Tasmar (tolcapone) is a small molecule pharmaceutical. Tolcapone was first approved as Tasmar on 1997-08-27. It is used to treat parkinson disease in the USA. It has been approved in Europe to treat parkinson disease. The pharmaceutical is active against catechol O-methyltransferase. In addition, it is known to target catechol O-methyltransferase.
|Drug Class||Catechol-O-methyltransferase (COMT) inhibitors|